Kornimate/medical-research-clean huggingface dataset:
multipolar mapping and atrial arrhythmias

Conditions: Atrial Fibrillation or Atrial Flutter

Summary: this clinical investigation utilizes the constellation full contact mapping catheter in the left and right atria to explore atrial signal characteristics that can guide atrial fibrillation and atrial flutter ablation procedures more effectively.

atrial fibrillation (af) and atrial flutter (afl) are the most common cardiac arrhythmias in adults, and account for a substantial portion of patient morbidity and healthcare expenditures. great effort has been put forth to discover effective treatments for af/fl. promising results of catheter ablation suggest that af/fl may be eliminated in a majority of patients. for example, data from numerous laboratories shows that up to 85 percent of patients with the paroxysmal form of af may be free of recurrences and off anti-arrhythmic drugs at one year follow-up.

Eligibility criteria:
inclusion criteria: patients referred to the pi (dr. biviano) or co-investigators in the program of cardiac electrophysiology at columbia university medical center who are scheduled to undergo ablation will be approached for recruitment: * older than 45 years of age * history of af and/or afl and are candidates for catheter ablation. exclusion criteria: patients not fitting the above clinical criteria or unwilling to comply with the instructions of the monitor are excluded, as well as patients with the following: * permanent leads or prosthetic or stenotic valves present * active systemic infection * echocardiographically-confirmed visual presence of thrombus * for whom the inability of obtaining vascular access exists * heparin-induced thrombocytopenia * hemodynamic instability or shock

Keywords: atrial fibrillation atrial flutter multipolar catheter atrial arrhythmia
probiotic supplementation for those immune non-responders with hiv-1 infection

Conditions: HIV-infection/Aids

Summary: gut bacterial community diversity and composition, immune recovery and activation in peripheral plasma/mucosa, plasma levels of gut damage, microbial translocation and inflammation at baseline and after 6 months of receiving intervention will be analyzed.

up to 25% of hiv-infected individuals receiving antiretroviral treatment demonstrate suboptimal blood cluster of differentiation 4（cd4） recovery despite effective viral suppression; this "immunologic non-responder" (inr) phenotype is associated with increased immune activation and with higher rates of aids and non-aids related conditions, and death. poor gut integrity, increased microbial translocation, and reduced cd4 t-cell trafficking to the gut could be a source of ongoing inflammation in inr individuals. researches have shown that the gut microbiota compositions are different in inrs and immunological responders (irs). probiotics, by modulation of gut microbiota, can help induce epithelial healing and prevent bacterial translocation. probiotic supplementation, therefore, may be a nutritional target for inrs by boosting cd4 cell counts. we design a prospective, case-control, self-contrast study to explore the efficacy and safety of probiotic supplementation in inrs. participants will receive oral probiotic containing 3 billion bifidobacterium and 1 billion lactobacillus once daily. gut bacterial community diversity and composition, immune recovery and activation in peripheral plasma/mucosa, plasma levels of gut damage, microbial translocation and inflammation at baseline and after 6 months of receiving intervention will be analyzed.

Eligibility criteria:
inclusion criteria: * documented hiv-1 infection * 18-65 years old * on antiretroviral therapy (\>2 years) * ability to provide informed consent * undetectable plasma hiv-1 viral load for the past 2 years * cd4 t-cell count \<350/mm3 for the last 2 years * no history of gastrointestinal diseases exclusion criteria: * administration of antibiotics, probiotics, or prebiotics or experience of diarrhea within the previous 3 months; * administration of anti-inflammatory drugs, corticosteroids, immunosuppressive drugs, immunomodulator within the previous 3 months; * severe organ dysfunction * pregnancy or breastfeeding
transversus abdominis plane block in pediatrics: volume or concentration ?

Conditions: Inguinal or Ovarian Hernia; Hydrocele; Cord Kyst; Local Analgesia Block; One to Five Years

Summary: the transversus abdominis plane (tap) block provide a local anesthesia drug diffusion between the transverse abdominis muscle and the internal oblique muscle. tap block reaches the anterior rami of spinal nerves from t7 to l1 involved in the innervation of homolateral abdominal wall. the transversus abdominis plane block has shown promise for perioperative analgesia, but data on the optimal dose regimen are limited.following previous research of optimal dose of local anesthesic solution, the investigators aim to evaluate if a "volume effect" would lead to a better diffusion of the local anesthesic solution to the overall nervous roots. the local anesthesia drug choosen is levobupivacaine with a unique posology of 0,4 mg/kg (either 0,2 ml/kg of 0,2% levobupivacaine for "small volume" group or 0,4 ml/kg of 0,1% levobupivacaine for "high volume" group).with the same dose of levobupivacaine, this study aims to assess the impact of volume effect on analgesia efficiency as well as the security as after ultrasound tap block on one to five years' old children who undergo a peritoneal-vaginal duct surgery.


Eligibility criteria:
inclusion criteria: * hospitalisation in ambulatory surgery and anesthesia unit for surgery of inguinal hernia or ovarian hernia or hydrocele or cord kyst * overall status: asa i-ii * aged from 1 to 5 years * informed consent exclusion criteria: * coagulation trouble * infection on ponction zone * local anesthesia drug or nonsteroidal anti inflammatory intolerance * cardiac/renal/hepacticdysfunction * hemorrage, digestive perforation history

Keywords: regional anesthesia tap block pediatric anesthesia analgesic effects pharmacokinetics
pudendal block versus caudal block for hypospadias

Conditions: Pain

Summary: the aim of this prospective randomized study is to assess the analgesic efficacy and duration of pudendal block compared with caudal block for pediatric patients undergoing hypospadias surgery concerning intraoperative analgesic and also postoperative total analgesic consumption within 24 hours.

in this prospective study, patients will be randomized into 2 groups, either receiving caudal block(cb) or nerve stimulator-guided pudendal nerve block(pnb). analgesic consumption will be assessed during the first 24 hours postoperatively. the "cheops pain scale" will use to assess postoperative pain.

Eligibility criteria:
inclusion criteria: * asa physical status i-ii * aged 1 to 10 years scheduled undergoing hypospadias surgery exclusion criteria: * history of allergic reactions to local anesthetics * rash or infection at the injection site * anatomical abnormality * bleeding diatheses, coagulopathy, liver diseases

Keywords: pudendal block hypospadias caudal block child analgesia
development of an artificial intelligence algorithm

Conditions: Mechanical Intestinal Obstruction

Summary: mechanical obstruction of the small intestine is an interruption of intestinal transit due to an organic obstacle in the digestive tract that results in a shutdown of materials and gas. without medical care, it can lead to perforation of the intestinal wall and acute peritonitis. it accounts for 4% of emergency department admissions and 20% of emergency surgeries

the abdominopelvic tomodensitometric examination is the gold standard for making a diagnosis and identifying the cause, the level of the lesion and looking for signs of severity related to the risk of ischemia of the intestinal tissue. well characterized, these signs remain difficult to identify for a non-expert radiologist. the evaluation of the detection performance of these signs shows a sensitivity between 63 and 100% and a specificity between 61 and 96% with a great variation according to the signs studied. our research project aims to develop a tool for the detection of the three main signs of severity of mechanical intestinal obstruction to raise and standardize the level of detection of the risk of ischemia on abdominal ct images.

Eligibility criteria:
inclusion criteria: * patient whose age is ≥ 18 years * patients with an abdominal scan performed at saint-joseph hospital * patients diagnosed with mechanical obstruction of the small intestine on a flange or adhesion * patients having abdominal surgery within 48 hours of diagnosis or medical follow-up at saint joseph hospital * french-speaking patient exclusion criteria: * patients with a history of abdominal surgery one month before diagnosis * patients objecting to the use of their data for this research * patient under guardianship or curatorship * patient under legal protection * patient deprived of liberty

Keywords: ischemia
organ motion and early tumor response measurement

Conditions: Esophageal Cancer; Chemoradiation

Summary: to quantify motion based variation of the target volume of the primary tumor over the course of chemoradiotherapy in esophageal cancer patients, and to use this information to calculate appropriate ptv (planning target volume) margins according to the margins recipe for patients receiving trimodality (neoadjuvant chemoradiation and surgery) or definitive chemoradiation in order to personalize radiation treatment, resulting in either better target coverage or a reduction in normal tissue radiation exposure.

a single center prospective observational study will be performed in esophageal cancer patients. this study registers motion of the esophageal tumor, using 4d planning ct scans and repeated 4d cbct scanning. motion of fiducial markers inserted into the esophageal wall, will be used as a surrogate for tumor motion in the limited image quality of cbct scans. patients planned for trimodality treatment will additionally be imaged by serial 4d pet ct and mri in week 0 (before start chemoradiotherapy), week 3 (during chemoradiotherapy) and week 10 (just prior to surgery) to observe (early) signs of tumor response. patients planned for definitive chemoradiation will not receive extra mri imaging during treatment because of the inability to correlate this imaging with pathological response.

Eligibility criteria:
inclusion criteria: 1. histologic evidence of invasive adenocarcinoma or squamous cell cancer of the esophagus 2. patient eligible for trimodality treatment (chemoradiotherapy and surgery) or definitive chemoradiotherapy 3. t3n0m0 or t1-4n1-3m0. patients with m1 disease solely on the basis of supraclavicular metastasis and not a junction tumor as primary are eligible. (ajcc 7th edition,). 4. who performance status ≤2 (who scale) 5. clinically operable for r0 resection in the opinion of an experienced upper gastrointestinal or thoracic surgeon for patients planned for trimodality 6. tumor localization at least 2cm from the upper esophageal sphincter and invading no more than 5cm into gastric cardia 7. age ≥ 18 years 8. written informed consent before endoscopy or eus exclusion criteria: 1. prior treatment with thoracic surgery or thoracic radiotherapy 2. pregnancy 3. severe cardiopulmonary restriction

Keywords: esophageal cancer chemoradiation
a trial investigating the total exposure of nn5401 (insulin degludec/insulin aspart) in children, adolescents and adult subjects with type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial was conducted in europe. the aim of this study was to investigate the total exposure of nn5401 (insulin degludec/insulin aspart) in children, adolescents and adult subjects with type 1 diabetes.


Eligibility criteria:
inclusion criteria: * type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months * body mass index for children: 15.0-20.0 kg/m\^2 (both inclusive), for adolescents: 18.0-28.0 kg/m\^2 (both inclusive) and for adults maximum 30.0 kg/m\^2 exclusion criteria: * subject who has donated any blood or plasma in the past month, or more than 500 ml within 3 months prior to screening * not able or willing to refrain from smoking during the inpatient period * female of childbearing potential who is pregnant, breast-feeding or intends to become pregnant or is not using adequate contraceptive methods
treatment of polypoidal choroidal vasculopathy in pachychoroid

Conditions: Choroidal Neovascularization; Choroid Disease

Summary: this study will evaluate patients with diagnosis of polypoidal choroidal vasculopathy (pcv) in pachychoroid treated with combined therapy, consisting in photodynamic therapy (pdt) and 3 intravitreal therapy (ivt) of aflibercept monthly. this is a single center, prospective case-series study. the investigators are going to evaluate corrected distance visual acuity (cdva), disease activity, retinal and choroidal thicknesses and number of injection per year, during a twelve month follow up. the aim of this study is to verify if the combined therapy can act on the insult induced by the pachychoroid and on the neovascular lesion itself in this sub-population of patients with pcv in pachychoroid,

this study evaluates patients with diagnosis of polypoidal choroidal vasculopathy (pcv) in pachychoroid treated with combined therapy, consisting in photodynamic therapy (pdt) and 3 intravitreal therapy (ivt) of aflibercept monthly. inclusion criteria are the presence of haemorrhagic or exudative pcv diagnosed by optical coherence tomography (oct) and indocyanine green angiography (icga) and the mean central choroidal thickness \> 250 µm. exclusion criteria comprehend ocular comorbidity, previous cardiovascular events and different ocular surgical procedures form cataract surgery. participants undergo a thorough ophthalmic assessment that included best corrected visual acuity (cdva), slit lamp biomicroscopy and dilated funduscopic examination. oct, oct-angiography (oct-a), icga and fluoresceine angiography (fa) were performed for all patients. the 12-month follow-up foresee monthly revaluations of the above measurements, excluding fa, repeated only on clinical judgement. cdva will be measured using logmar. choroidal and retinal thicknesses will be automatically measured by digital software oct- integrated (imagenet). all patients will be treated with a loading dose of aflibercept combined with pdt within the first 7 days of the first intravitreal therapy. the spot size is calculated by adding 1000 μm to the greater linear dimension of the lesion. no additional therapy will be performed during follow-up unless signs of reactivation.

Eligibility criteria:
inclusion criteria: * presence of haemorrhagic or exudative pcv diagnosed by oct and icga * mean central choroidal thickness \> 250 µm exclusion criteria: * ocular comorbidity * previous cardiovascular events * different ocular surgical procedures form cataract surgery

Keywords: pachychoroid polypoidal choroidal vasculopathy aflibercept photodynamic therapy swept source oct
photodynamic therapy using porfimer sodium in treating patients with recurrent mouth or throat dysplasia or recurrent in situ cancer or stage i cancer of the mouth or throat

Conditions: Head and Neck Cancer

Summary: rationale: photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. when the drug is active, tumor cells are killed. photodynamic therapy using porfimer sodium may be effective against mouth or throat dysplasia and cancer of the mouth and throat. purpose: this phase i trial is studying how well photodynamic therapy using porfimer sodium works in treating patients with recurrent mouth or throat dysplasia, recurrent in situ cancer of the mouth or throat, or stage i cancer of the mouth or throat.

objectives: * to determine the response of patients with recurrent dysplasia, squamous cell carcinoma in situ, or stage i squamous cell carcinoma of the oral cavity or the larynx treated with photodynamic therapy using porfimer sodium. * to identify the local toxicity of this treatment in these patients. outline: patients receive porfimer sodium subcutaneously followed by photodynamic therapy (pdt) comprising laser light delivered by a single or a diffuser (i.e., for broad areas of dysplasia) fiberoptic lens fiber. patients with incompletely treated or missed sites of disease may receive another dose of laser light on day 5 without additional porfimer sodium. patients with multicentric disease may undergo additional pdt at least 4-6 weeks after the initial treatment. after completion of study therapy, patients are followed for 1-2 months.

Eligibility criteria:
disease characteristics: * biopsy confirmed oral cavity or larynx lesion with mild-to-severe dysplasia or in situ or stage i (t1, n0) squamous cell carcinoma of the oral cavity or larynx * recurrent disease patient characteristics: * ecog performance status 0-2 * wbc ≥ 4,000/mm\^3 * platelet count ≥ 100,000/mm\^3 * total bilirubin ≤ 2.0 mg/dl * creatinine ≤ 2.0 mg/dl * alkaline phosphatase ≤ 3 times upper limit of normal (uln) * sgot ≤ 3 times uln * not pregnant or nursing * negative pregnancy test * fertile patients must practice effective contraception * no porphyria or hypersensitivity to porphyrin or porphyrin-like compounds prior concurrent therapy: * any type of prior therapy allowed * more than 4 weeks since prior and no concurrent chemotherapy or radiotherapy

Keywords: recurrent squamous cell carcinoma of the larynx recurrent squamous cell carcinoma of the lip and oral cavity stage i squamous cell carcinoma of the larynx stage i squamous cell carcinoma of the lip and oral cavity stage 0 laryngeal cancer stage 0 lip and oral cavity cancer
role of low carbohydrate nutrient in healing of infected diabetic foot

Conditions: Carbohydrate Ingestion

Summary: a low-carbohydrate diet, when combined with standard wound care and diabetes management, appears to accelerate the healing of infected diabetic foot, improve blood glucose control, reduce systemic inflammation and promoting overall patient recovery. this approach could be considered a beneficial adjunct therapy in the treatment of diabetic foot infections.

the research was a case control study. it conducted prospectively from january 2019 to december 2023 in the surgery department of aswan university hospital. it involving patients with diabetic foot infections. the patients were divided into two groups of patients. the first group committed to not eating carbohydrates in food. the second group ate their daily routine and did not adhere to the carbohydrate's restriction. the diabetic food infection classified from mild, moderate and sever, as per the infectious diseases society of america (idsa) infection severity classification.

Eligibility criteria:
inclusion criteria: patients complained of diabetic foot infections graded 0 to 4 with absent signs of ischemia. exclusion criteria: patients with foot gangrene grade 5 the presence of foot ischemia those who refused to participate

Keywords: diabetic foot wound infections, diabetic foot ulcer, low carbohydrate dietary approaches.
high-flow nasal oxygen in palliative care: pilot study

Conditions: Dyspnea

Summary: in palliative care, the relief of the dyspnea is necessary. medications for the reduction of dyspnea have side effects. high-flow nasal cannula oxygen therapy (hfnc) is a new way to deliver oxygen. investigators hypothesize that hnfc is an acceptable technic for the patient with dyspnea in palliative care. a pilot study with 30 patients will be conducted. acceptability of hnfc will be studied by the time of use by patients of the hnfc during one week. the effectiveness of hnfc in relieving dyspnea will be studied using borg scale.

pilot study for acceptability of high flow nasal cannula oxygen therapy in palliative care population: 30 patients in palliative care (for lung cancer, terminal respiratory failure) who suffer from dyspnea and have oxygen therapy. patients with curative care are excluded and patients who require non invasive ventilation. an oral consent is asked. primary objective: acceptability of hnfc in patients with dyspnea in palliative care during one week secondary objectives: * tolerance of hnfc at short term (1h and 24h) and long term (7 days) after initiation of hnfc * efficiency of hnfc at short term primary outcome: duration of use of the hnfc during 7 days secondary outcome: * tolerance: noise of the system of hnfc, side effects of high flow (nasal dryness..) * efficiency: evaluation of dyspnea by borg scale and measure of respiratory rate and saturation of oxygen one hour after initiation of hnfc

Eligibility criteria:
inclusion criteria: * patient followed for respiratory failure with palliative care and : * more than 18 years old * dyspnea related to a respiratory disease * hypoxemia requiring the introduction of more than 4 liters of oxygen for a sp02 \> 90% * patient affiliated to a social security system exclusion criteria: * patient less than 18 years old * patient with guardianship, trusteeship * no consent for participation at the study * project of curative care

Keywords: dyspnea palliative care high-flow nasal oxygen pilot study
intra-operative metrics with centurion® and infiniti® vision systems

Conditions: Cataract

Summary: the purpose of this study is to evaluate intra-operative phacoemulsification machine metrics after phacoemulsification with the centurion® vision system configuration compared with the infiniti® vision system configuration.


Eligibility criteria:
inclusion criteria: * eligible to undergo cataract extraction via phacoemulsification with primary acrysof intraocular lens (iol) implantation; * free of severe disease(s)/condition(s) listed in the "warnings" and "precautions" section of implanted acrysof iol; * willing to undergo second eye surgery within 14 days of first eye surgery; * willing and able to understand/sign a written informed consent document; * willing and able to return for scheduled follow-up examinations; * other protocol-defined inclusion criteria may apply. exclusion criteria: * planned multiple procedures at the time of surgery or during the course of the study (eg, lasik, lri, etc.); * previous intraocular or corneal surgery of any kind; * poorly dilating pupil; * severe retinal disorders (eg, macular degeneration, proliferative diabetic retinopathy); * corneal disease (eg, herpes simplex, herpes zoster, etc) or retinal detachment; * severe conditions that per investigator's clinical judgment would increase the operative risk or confound the result of this investigation; * female patients who are pregnant, lactating, or planning to be pregnant during the course of the study; * currently participating in another drug or device clinical trial, or participated in another drug or device clinical trial within 30 days of enrollment into this trial; * other protocol-defined exclusion criteria may apply.

Keywords: cataract phacoemulsification cumulative dissipated energy (cde)